Maintenance tyrosine kinase inhibitors following allo-HCT for chronic myeloid leukemia: A CIBMTR Study.

DeFilipp, Zachariah; Ancheta, Richard; Liu, Ying; Hu, Zhen-Huan; Gale, Robert Peter; Snyder, David; Schouten, Harry C; Kalaycio, Matt; Hildebrandt, Gerhard C; Ustun, Celalettin; Daly, Andrew; Ganguly, Siddhartha; Inamoto, Yoshihiro; Litzow, Mark; Szer, Jeffrey; Savoie, Mary Lynn; Hossain, Nasheed; Kharfan-Dabaja, Mohamed A; Hamadani, Mehdi; Reshef, Ran; ... (2019). Maintenance tyrosine kinase inhibitors following allo-HCT for chronic myeloid leukemia: A CIBMTR Study. (In Press). Biology of blood and marrow transplantation Elsevier 10.1016/j.bbmt.2019.10.017

[img] Text
Maintenance.pdf - Accepted Version
Restricted to registered users only until 26 October 2020.
Available under License Creative Commons: Attribution-Noncommercial-No Derivative Works (CC-BY-NC-ND).

Download (899kB) | Request a copy

It remains unknown whether the administration of tyrosine kinase inhibitors (TKIs) targeting BCR-ABL1 after allogeneic hematopoietic cell transplantation (HCT) is associated with improved outcomes for patients with chronic myeloid leukemia (CML). In this registry study, we analyzed clinical outcomes of 390 adult patients with CML transplanted from 2007-2014 who received maintenance TKI following HCT (n=89) as compared to no TKI maintenance (n=301), as reported to the Center for International Blood and Marrow Transplant Research. All patients received TKI therapy prior to HCT. The majority of patients had disease beyond CP1 at HCT (n=240, 62%). The study was conducted as a landmark analysis, excluding patients that died, relapsed, had chronic graft-versus-host disease or were censored prior to Day 100 following HCT. Of the 89 patients receiving TKI maintenance, 77 (87%) received a single TKI while 12 (13%) received multiple sequential TKIs. The most common TKIs used for maintenance were dasatinib (n=50), imatinib (n=27) and nilotinib (n=27). As measured from Day 100, the adjusted estimates for 5-year relapse (maintenance, 35% vs. no maintenance, 26%; p=0.11), leukemia-free survival (LFS, maintenance, 42% vs. no maintenance, 44%; p=0.65) or overall survival (OS, maintenance, 61% vs. no maintenance, 57%; p=0.61) did not significantly differ between patients receiving TKI maintenance or no maintenance. These results remained unchanged in multivariate analysis and were not modified by the status of disease prior to transplant. In conclusion, our data did not demonstrate a significant impact of maintenance TKI therapy on clinical outcomes in a Day 100 landmark analysis. The optimal approach to TKI administration in the post-transplant setting in CML remains undetermined.

Item Type:

Journal Article (Original Article)

Division/Institute:

04 Faculty of Medicine > Department of Haematology, Oncology, Infectious Diseases, Laboratory Medicine and Hospital Pharmacy (DOLS) > Clinic of Haematology and Central Haematological Laboratory

UniBE Contributor:

Bacher, Vera Ulrike

Subjects:

600 Technology > 610 Medicine & health

ISSN:

1083-8791

Publisher:

Elsevier

Language:

English

Submitter:

Pierrette Durand Lüthi

Date Deposited:

13 Nov 2019 15:48

Last Modified:

13 Nov 2019 15:48

Publisher DOI:

10.1016/j.bbmt.2019.10.017

PubMed ID:

31669399

Uncontrolled Keywords:

Allogeneic hematopoietic cell transplantation Chronic myeloid leukemia Maintenance Tyrosine kinase inhibitor

BORIS DOI:

10.7892/boris.134704

URI:

https://boris.unibe.ch/id/eprint/134704

Actions (login required)

Edit item Edit item
Provide Feedback